Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Study: Patients switched to AROMASIN more likely to remain cancer-free
April 6th, 2004
Postmenopausal breast cancer patients who switched from tamoxifen to AROMASIN (exemestane tablets) had a significantly reduced chance of recurrence and increased disease-free survival compared to patients who remained on tamoxifen, according to new data published recently. The Intergroup Exemestane Study (IES) involved more than 4700 postmenopausal women in 37 countries with breast cancer who were followed for an average of 31 months. According to a current treatment paradigm, postmenopausal women with estrogen-receptor positive breast cancer receive tamoxifen for 5 years after surgery to prevent recurrence. The IES study demonstrated that patients...
Source: Cancer Weekly (2004-04-06)
|
